Zura Bio Limited (Nasdaq: ZURA)

Strong Women. Strong Leadership. Lasting Impact. This Women’s History Month, we recognize the contributions of women who drive change and lead with impact. Congratulations to Kim A Davis on her expanded role as Chief Operating Officer (COO) and Chief Legal Officer (CLO)! She has played a key role in legal strategy, compliance, and safeguarding the organization’s integrity, all while supporting key operational initiatives. Now, as COO, she continues to enhance operations, strengthen teams, and foster excellence. #WomensHistoryMonth #WomenInLeadership #TeamZura

We had an engaging week at the Leerink Partners Global Healthcare Conference in Miami!?? ? A special thank you to?Faisal Khurshid for hosting an informative discussion with our CEO, Robert Lisicki, highlighting our recent progress, key initiatives, and future opportunities.

Autoimmune diseases occur when the immune system mistakenly attacks healthy tissue instead of protecting it. With over 100 known autoimmune diseases affecting millions worldwide, their exact causes remain unclear. At Zura Bio, we are advancing TibuSURE, a Phase 2 clinical trial evaluating tibulizumab in systemic sclerosis (#SSc) and preparing to initiate a study in hidradenitis suppurativa (#HS) in 2Q 2025. Our goal is to explore potential new treatment options for these chronic, immune-driven diseases. Learn more:?https://lnkd.in/eDB6Bp3h #AutoimmuneAwarenessMonth #ZuraBio #TibuSURE

Today is Rare Disease Day! On this important day, we’re spotlighting a vital conversation on rare disease research. Our CMO, Kiran Nistala, MBBS, PhD, joined Karen Jagoda on?The Empowered Patient?Podcast to discuss the challenges, progress, and need for continued innovation to support the 300 million people living with rare diseases. At Zura Bio, we stand with the rare disease community. Our TibuSURE Phase 2 trial for systemic sclerosis (#SSc) reflects our commitment to exploring potential treatment options for those with limited choices. ???Listen here: https://lnkd.in/eFttZhgP ? #RareDiseaseDay #EmpoweredPatientPodcast #RareDiseaseAwareness #SystemicSclerosis #ZuraBio #TibuSURE

Join #TeamZura at the Leerink Partners Global Healthcare Conference 2025 in Miami, FL, from March 9-12. Our senior leadership will provide key updates on our pipeline, including the ongoing Phase 2 TibuSURE trial in systemic sclerosis (#SSc) and our planned trial in hidradenitis suppurativa (#HS) with tibulizumab.?? ? For full conference details, check out our press release here: https://lnkd.in/eeuJuSyi

Rare Disease Day is on February 28! Over 300 million people worldwide live with rare diseases, often facing significant challenges in diagnosis, treatment, and care. At Zura Bio, we are committed to supporting this community and advancing potential solutions. Our TibuSURE Phase 2 trial for systemic sclerosis (#SSc) reflects our dedication to exploring better treatment options for those living with rare conditions. Let’s raise awareness, support patients and caregivers, and work toward a future filled with hope and more options for those affected by rare diseases. ?? Learn more: rarediseaseday.org #RareDiseaseDay #RareDiseaseAwareness #ZuraBio #TibuSURE

#ICYMI: Our CMO, Kiran Nistala, MBBS, PhD, shared his insights with PharmaVoice on the potential to streamline #raredisease drug development. Check out the featured series here: https://lnkd.in/et5482xq

That’s a wrap on an exciting #JPMWeek in San Francisco! #TeamZura made meaningful connections with industry peers, investors, and partners, sharing recent progress on our pipeline of novel dual-pathway antibody candidates and the exciting milestones we anticipate in the year ahead. #JPM25

We’re grateful to have our Phase 2 TibuSURE study featured on the Nasdaq Tower in Times Square! #ICYMI: We recently launched a global Phase 2 study to evaluate tibulizumab in adults with systemic sclerosis (#SSc), a rare autoimmune disease. This marks an important step in advancing potential new treatment options for SSc and supporting those living with this condition. #SystemicSclerosis #ClinicalTrials #TibuSURE #tibulizumab #Nasdaq Photo courtesy of ?2025 Nasdaq, Inc.

Zura Bio Limited (Nasdaq: ZURA) is heading to #JPM25 next week! We’re excited to start the year by connecting with industry peers, partners, and investors to discuss our innovative pipeline of dual-pathway antibody candidates, including the clinical development of #tibulizumab for systemic sclerosis (#SSc) and hidradenitis suppurativa (#HS). See you in San Francisco!